MaaT Pharma raise 18m to advance clinical pipeline
MaaT Pharma SA has announced 18m Series B financing to boost its microbiome biotherapeutics pipeline.
Stilla raises 20m in series B financing round
French Stilla Technologies SA raised 20m in a Series B funding to boost digital PCR-based genetic testing.
Valneva raises US$85m
French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
Sleeping sickness target deciphered
Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.
UK researchers present dengue virus transmission map
Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.
AMR: IMIs Enable project reaches endpoints
The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.
MercachemSyncom, Bionetix, and ProQinase ink AML contract
Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing
iOnctura SA bags 15m in Series A round
Merck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised 15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.
BioNTech acquires Neon at cheapest for $67m
mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.